New and old roles of the peripheral and brain renin–angiotensin–aldosterone system (RAAS): Focus on cardiovascular and neurological diseases

A. R. Mascolo, M. Sessa, Cristina Scavone, A. De Angelis, C. Vitale, Liberato Berrino, F. Rossi, G. Rosano, A. Capuano

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

It is commonly accepted that the renin–angiotensin–aldosterone system (RAAS) is a cardiovascular circulating hormonal system that plays also an important role in the modulation of several patterns in the brain. The pathway of the RAAS can be divided into two classes: the traditional pathway of RAAS, also named classic RAAS, and the non-classic RAAS. Both pathways play a role in both cardiovascular and neurological diseases through a peripheral or central control. In this regard, renewed interest is growing in the last years for the consideration that the brain RAAS could represent a new important therapeutic target to regulate not only the blood pressure via central nervous control, but also neurological diseases. However, the development of compounds able to cross the blood–brain barrier and to act on the brain RAAS is challenging, especially if the metabolic stability and the half-life are taken into consideration. To date, two drug classes (aminopeptidase type A inhibitors and angiotensin IV analogues) acting on the brain RAAS are in development in pre-clinical or clinical stages. In this article, we will present an overview of the biological functions played by peripheral and brain classic and non-classic pathways of the RAAS in several clinical conditions, focusing on the brain RAAS and on the new pharmacological targets of the RAAS.

Original languageEnglish
Pages (from-to)734-742
JournalInternational Journal of Cardiology
Volume227
DOIs
Publication statusPublished - 2017

Fingerprint

Cardiovascular Diseases
Brain
Glutamyl Aminopeptidase
Half-Life
Pharmacology
Blood Pressure
Pharmaceutical Preparations
Therapeutics

Keywords

  • Angiotensin
  • Coronary artery disease
  • Heart failure
  • Neurological diseases
  • Pharmacology
  • Renin–angiotensin–aldosterone system

ASJC Scopus subject areas

  • Medicine(all)
  • Cardiology and Cardiovascular Medicine

Cite this

New and old roles of the peripheral and brain renin–angiotensin–aldosterone system (RAAS) : Focus on cardiovascular and neurological diseases. / Mascolo, A. R.; Sessa, M.; Scavone, Cristina; De Angelis, A.; Vitale, C.; Berrino, Liberato; Rossi, F.; Rosano, G.; Capuano, A.

In: International Journal of Cardiology, Vol. 227, 2017, p. 734-742.

Research output: Contribution to journalReview article

@article{21a0ef81623a46be8cb7f9a93dac8208,
title = "New and old roles of the peripheral and brain renin–angiotensin–aldosterone system (RAAS): Focus on cardiovascular and neurological diseases",
abstract = "It is commonly accepted that the renin–angiotensin–aldosterone system (RAAS) is a cardiovascular circulating hormonal system that plays also an important role in the modulation of several patterns in the brain. The pathway of the RAAS can be divided into two classes: the traditional pathway of RAAS, also named classic RAAS, and the non-classic RAAS. Both pathways play a role in both cardiovascular and neurological diseases through a peripheral or central control. In this regard, renewed interest is growing in the last years for the consideration that the brain RAAS could represent a new important therapeutic target to regulate not only the blood pressure via central nervous control, but also neurological diseases. However, the development of compounds able to cross the blood–brain barrier and to act on the brain RAAS is challenging, especially if the metabolic stability and the half-life are taken into consideration. To date, two drug classes (aminopeptidase type A inhibitors and angiotensin IV analogues) acting on the brain RAAS are in development in pre-clinical or clinical stages. In this article, we will present an overview of the biological functions played by peripheral and brain classic and non-classic pathways of the RAAS in several clinical conditions, focusing on the brain RAAS and on the new pharmacological targets of the RAAS.",
keywords = "Angiotensin, Coronary artery disease, Heart failure, Neurological diseases, Pharmacology, Renin–angiotensin–aldosterone system",
author = "Mascolo, {A. R.} and M. Sessa and Cristina Scavone and {De Angelis}, A. and C. Vitale and Liberato Berrino and F. Rossi and G. Rosano and A. Capuano",
year = "2017",
doi = "10.1016/j.ijcard.2016.10.069",
language = "English",
volume = "227",
pages = "734--742",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - New and old roles of the peripheral and brain renin–angiotensin–aldosterone system (RAAS)

T2 - Focus on cardiovascular and neurological diseases

AU - Mascolo, A. R.

AU - Sessa, M.

AU - Scavone, Cristina

AU - De Angelis, A.

AU - Vitale, C.

AU - Berrino, Liberato

AU - Rossi, F.

AU - Rosano, G.

AU - Capuano, A.

PY - 2017

Y1 - 2017

N2 - It is commonly accepted that the renin–angiotensin–aldosterone system (RAAS) is a cardiovascular circulating hormonal system that plays also an important role in the modulation of several patterns in the brain. The pathway of the RAAS can be divided into two classes: the traditional pathway of RAAS, also named classic RAAS, and the non-classic RAAS. Both pathways play a role in both cardiovascular and neurological diseases through a peripheral or central control. In this regard, renewed interest is growing in the last years for the consideration that the brain RAAS could represent a new important therapeutic target to regulate not only the blood pressure via central nervous control, but also neurological diseases. However, the development of compounds able to cross the blood–brain barrier and to act on the brain RAAS is challenging, especially if the metabolic stability and the half-life are taken into consideration. To date, two drug classes (aminopeptidase type A inhibitors and angiotensin IV analogues) acting on the brain RAAS are in development in pre-clinical or clinical stages. In this article, we will present an overview of the biological functions played by peripheral and brain classic and non-classic pathways of the RAAS in several clinical conditions, focusing on the brain RAAS and on the new pharmacological targets of the RAAS.

AB - It is commonly accepted that the renin–angiotensin–aldosterone system (RAAS) is a cardiovascular circulating hormonal system that plays also an important role in the modulation of several patterns in the brain. The pathway of the RAAS can be divided into two classes: the traditional pathway of RAAS, also named classic RAAS, and the non-classic RAAS. Both pathways play a role in both cardiovascular and neurological diseases through a peripheral or central control. In this regard, renewed interest is growing in the last years for the consideration that the brain RAAS could represent a new important therapeutic target to regulate not only the blood pressure via central nervous control, but also neurological diseases. However, the development of compounds able to cross the blood–brain barrier and to act on the brain RAAS is challenging, especially if the metabolic stability and the half-life are taken into consideration. To date, two drug classes (aminopeptidase type A inhibitors and angiotensin IV analogues) acting on the brain RAAS are in development in pre-clinical or clinical stages. In this article, we will present an overview of the biological functions played by peripheral and brain classic and non-classic pathways of the RAAS in several clinical conditions, focusing on the brain RAAS and on the new pharmacological targets of the RAAS.

KW - Angiotensin

KW - Coronary artery disease

KW - Heart failure

KW - Neurological diseases

KW - Pharmacology

KW - Renin–angiotensin–aldosterone system

UR - http://www.scopus.com/inward/record.url?scp=85003839013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003839013&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2016.10.069

DO - 10.1016/j.ijcard.2016.10.069

M3 - Review article

VL - 227

SP - 734

EP - 742

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -